(R)-(+)-5-hydroxy-2,4,6,7-tetramethyl-2,3-dihydrobenzofuran-2-carboxylic acid | 118100-80-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 香豆素
• 英文名称: (R)-(+)-5-hydroxy-2,4,6,7-tetramethyl-2,3-dihydrobenzofuran-2-carboxylic acid
• 英文别名: (2R)-5-hydroxy-2,4,6,7-tetramethyl-3H-1-benzofuran-2-carboxylic acid
• CAS: 118100-80-4
• 化学式: C₁₃H₁₆O₄
• 分子量: 236.268
• InChiKey: RTMJEEGBSLYPQR-CYBMUJFWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  17.0
• 可旋转键数：
  1.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  66.76
• 氢给体数：
  2.0
• 氢受体数：
  3.0

反应信息

• 作为反应物：
  描述：

  (R)-(+)-5-hydroxy-2,4,6,7-tetramethyl-2,3-dihydrobenzofuran-2-carboxylic acid 在 吡啶 、 chromium(VI) oxide 、 lithium aluminium tetrahydride 、 potassium carbonate 作用下， 以 乙醚 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 25.67h， 生成 (S)-5-(benzyloxy)-2,4,6,7-tetramethyl-2,3-dihydrobenzofuran-2-carbaldehyde
  参考文献：
  名称：

  Chiral effects on the carbon-13 resonances of .alpha.-tocopherol and related compounds. A novel illustration of Newman's "rule of six"

  摘要：

  DOI：

  10.1021/jo00264a012
• 作为产物：
  描述：

  Acetic acid 4-acetoxy-2-(2-cyano-2-hydroxy-2-methyl-ethyl)-3,5,6-trimethyl-phenyl ester 在 盐酸 作用下， 反应 18.0h， 生成 (R)-(+)-5-hydroxy-2,4,6,7-tetramethyl-2,3-dihydrobenzofuran-2-carboxylic acid
  参考文献：
  名称：

  Chiral effects on the carbon-13 resonances of .alpha.-tocopherol and related compounds. A novel illustration of Newman's "rule of six"

  摘要：

  DOI：

  10.1021/jo00264a012

文献信息

• COMPOSITIONS AND METHODS FOR THE PREVENTION AND/OR TREATMENT OF MITOCHONDRIAL DISEASE, INCLUDING FRIEDREICH'S ATAXIA
  申请人：Keefe Dennis

  公开号：US20210206736A1

  公开（公告）日：2021-07-08

  The disclosure provides therapeutic compositions (i.e., therapeutic agents) and methods of preventing or treating Friedreich's ataxia in a mammalian subject, reducing risk factors, signs and/or symptoms associated with Friedreich's ataxia (e.g., Complex I deficiency), and/or reducing the likelihood or severity of Friedreich's ataxia. The disclosure further provides novel intermediates for the production of said therapeutic compositions and related reduced versions of said therapeutic compositions, which reduce forms may also be used as therapeutic agents (or prodrugs of the therapeutic agent(s)).